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The Treatment of Chronic Uremia
BELDING H. SCRIBNER

Department of Medicine , University of Washington, Seattle

I will begin by telling a little about
the development of chronic dialysis. In
1959 we were working on a system to
prevent uremia in acute renal failure.
We were trying to develop a system to
which we could "hook" the patient
for as long as a week, so that we would
exactly mimic his normal kidney function during the period of acute renal
failure, and make his prognosis that
of a patient who had kidneys. The
system worked reasonably well. We
had to make a lot of modifications,
such as using a Skeggs-Leonard dialyzer with low resistance. We used a
large deep freeze as a dialysate reservoir because we could not afford to
change the bath every few hours. The
patient was on continuously. We had
to cool the external circuit to control
clotting problems and infection. We
actually had patients on this system for
as long as two weeks. It was important
to us that we h ad this system in operation at the time we first devised the
cannulas. (The cannulas were devised
by Dr. David Dillard , our surgical consultant, and Mr. Wayne Quinton. It is
amazing how well their original design
has held. As far as I know, it has not
been improved greatly, because the cannulas are still the weakest part of the
system.)
General Features of the Cannulas and
Shunt

The essential system has a long subcutaneous tunnel with a curve of 180°
into each vessel. The tunnel is to prevent infection, and the curve is to
stabi lize the cannula in the vessel. The
system does not clot because one tube
is in the artery and one tube is in the
vein, and the blood runs through. Of

course, it all depends on tefion for
non-clotting. Allwall had tried the idea
in 1944 and failed, because he was
using glass cannulas and rubber tubing; we had a tefion system exclusively.
This is the basic operating principle
of the system: when you want to treat
a patient, you simply pull off the shunt,
connect the tubing to the artificial kidney, and you can dialyze at will. The
best evidence I can give that this system works is the first chronic patient
ever to receive cannulas. He is C lyde
Shields, who now has been five-andone-half years on dialysis. He has not
passed any urine in over five years,
and is today in better health than at
any time. We had to learn on our first
patients how to manage chronic uremia
by dialysis. We did not know how
much dialysis it would take, we did
not know how to take care of the
cannulas, and we did not know what
complications to expect. Clyde has his
present cannulas in his leg. We used
up all the arm sites in the first few
months because the straight tefton
system would last only a few months
and not much longer. The new rubber
segment has made a great difference in
the cannula system. The nurse used
to put the heparin into the bloodstream. We no longer do this, but use
an infusion pump. Note, though, that
the nurse does the entire procedure.
In Seattle, dialysis is completely nursetechnician operated on the chronic
program, and doctors are not in attendance.
We had our clear plastic Kiil dialyzer built especially to study dialyzerfiow pattern. One of the things that is
so important is a better understanding
of what is going across these mem-
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branes. If we could really understand
what the chemicals are that we had to
move, and urea is one of them, then
we could build better membranes. As
far as the technique of dialyzer design, ours is a good one but it is not
perfect. There is streaming, and the
minute you get streaming in a dialyzer,
you loose efficiency. We had this particular version built to study the flow
patterns. This Kiil dialyzer is the design of Dr. Frederick Kiil in Oslo. He
took the original Skeggs design and
modified it so that it was easier to assemble, and more efficient to use. This
is the only dialyzer at the present time
that has been proven useful in the
treatment of chronics, because it is low
in resistance, small in blood volume,
and easy to assemble. When the blood
finally reaches the venous end of the
external circuit, the nurse plugs the
venous candula in and the patient is on
dialysis.
For some idea of the progress being
made in the technology, where we
could formerly only treat three patients, we can now take four, thanks
to the central pumping system which
takes concentrate from a tank, and uses
very accurate proportioning pumps.
They mix the concentrate with tap
water, which is monitored by a conductivity meter, and then the fluid is
pumped around the room to the various stations. The whole system is automatic. This then means that we fill
this concentrate tank about once a
month instead of filling a tank once a
day for each patient.
Results of Management by Dialysis

We recently conducted a survey on
the current state of dialysis around the
world. There are 12 centers that have
been in operation for longer than oneand-one-half years. There are seven,
and probably more, newer groups just
getting started. There have been 95
patients taken into treatment. There
have been 28 deaths. What is most important is that 7 5 % of the deaths have
occurred during the first year of each
program . This underscores the need
for adequate preparation, adequate
funding, adequate training of personnel, and adequate creation of facilities
especially for chronic dialysis. This

also means that a realistic approach to
the problem is needed, rather than the
helter-skelter one that is so tempting
when you are confronted with a dying
patient. The other 25 % of the deaths
were due to what we considered to be
natural causes. In other words, the
one patient who died in Seattle, died
one year after starting the program, of
a myocardial infarction. And we certainly do not believe that dialysis is
going to prevent myocardial infarction.
In fact, these patients having only
moderately good control of their blood
pressures (some have normal and some
have moderate elevation of blood pressures), obviously are going to be more
prone to the vascular complications of
hypertension than the normal population. But these deaths are the natural
ones, and the other deaths can virtually
be eliminated with proper training and
proper preparation.
The rehabilitation rate should also
increase as treatment is started earlier,
so you will not be dealing with moribund patients. A lot of the failure to
rehabilitate has been due, for instance,
to starting with a moribund patient
who gets severe neuropathy. This has
been the case in our one failure to rehabilitate, and an early start would
avoid this. As far as prognosis is concerned, the longest one is our patient
who has been five-and-one-half years
on dialysis. He is in better health now
than he has been at any time.
Limitations of Dialysis in Children

If you take the ideal group, dialysis
seems to be contraindicated currently
in the adolescent and the child, because
we have failed to maintain normal
growth and to effect sexual maturity in
the one patient we treated in this way
in Seattle. This does not mean that, with
improved membranes and improved
techniques, we will not be able to maintain normal growth. And this will be
a very sensitive assay of the adequacy
of dialysis. Even when confining ourselves to the age group of 15 to 45, we
have about 25 new patients per one
million population per year. In the
United States, there are about 5,000
new patients per year. If the life expectancy is 10 years, this means there
will be a patient population of 50,000.

This is indeed a staggering number of
patients. When we think of our present
technology, no wonder adequate treatment seems impossible. On the other
hand, I think we are just scratching the
surface of what is possible technically,
and I would like to underscore that by
briefly covering some of the advances
made since the program began.
Problems and Complications

The first problem we faced was loss
of the cannulas. Mr. Quinton correctly
diagnosed the reason as due to stiffness
in the teflon. The system would not
give with the normal rotation of the
limb, and we lost the cannulas in a
matter of months due to mechanical
failure. Infection has occurred, of
course, but it is largely due to abuse
of the cannulas by the patient, and
inability to cooperate in his daily care.
Mr. Quinton worked one year to extrude silicone rubber tubing that would
not clot, after Dow-Corning said that
it could not be done. Now all patients
on chronic dialysis have this shock absorber in the system which greatly
prolongs the life of the cannulas. The
first patient to get this kind of cannula was in the program in Seattle, and,
three years later, he has the original
set. The usual life of these cannulas
extends from a few months to one-andone-half years, depending, mainly, on
how carefully the patient takes care of
his cannulated extremity. Certainly,
undue activity is the most important
factor in determining cannula failure.
We think the flexibility primarily accounts for the increased longevity of
the cannulas, compared with the old
teflon.
In Seattle, as in most centers, dialysis worked like this: it was an operating room procedure that took a
lot of work, a lot of people, and was
terribly expensive. Chronic dialysis
twice a week, using this approach, cost
from $20,000 to $30,000 per patient
per year. But in two years, starting with
the basic continuous system I mentioned, we have evolved the Seattle
continuous-flow, low-temperature system. We have turned it into a nursing
procedure. This makes possible, then,
the Seattle community center-type operation (under the direction of John
Murray, first, and now Jerry Pendras) ,
3
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where one nurse dialyses four patients
at once. The cost projections and the
pattern of operation of chronic dialysis all depend on the basic lessons
learned in this center, which was very
generously and very wisely funded by
the John A. Hartford Foundation in
1962. This center was built in the
basement of the nurses' home in Swedish Hospital. It shows what could be
done in the community, and that it
could be done outside the hospital or in
a low cost area. The cost of this type of
operation currently is $100 per dialysis,
or $10,000 per year for two treatments per week, including professional
fees. This is really the actual, total
cost. Rule off something such as construction and purchase of fixed equipment, and the cost is somewhat less.
We have made considerable progress
in understanding the diseases of dialysis. Clearly, all of these diseases, with
the exception of peripheral neuropathy, are due to inadequate dialysis.
The experience of the older days,
where you could not dialyze as much
as necessary, or the patients lost
weight, vomited, became malnourished,
and died, was simply because of inadequate dialysis. Gout, or gouty-like
arthritis which is an acute arthritis that
is responsive to colchicine and can be
reproduced by putting urate in the
bath, responds to adequate dialysis.
Metastatic calcifications dissolve if you
keep the phosphorous low enough with
dialysis, and peripheral neuropathy can
be stabilized by dialysis. But probably
the most important factor in peripheral
neuropathy in these patients is the
critical illness that may precede the
institution of therapy. Invariably, if
the patient becomes critically ill at the
time you start therapy, in a week or a
month he may develop a severe peripheral neuropathy. The degree of severity of this neuropathy varies tremendously from patient to patient, but
the clinical picture is constant. There
is now an excellent description of this
situation in the literature from the
Massachusetts General Hospital. The
prevention of neuropathy at this stage
of our understanding depends largely
on starting dialysis or doing the transplant before you are dealing with a
moribund patient. We have not yet

defined diseases due to much dialysis,
but because our membrane is nonspecific, I am sure that some will be
defined. Secondary hyperparathyroidism is not a problem, but anemia is a
continuing problem. The average requirement, if you rinse your dialyzer
properly, is about two units of blood
per month. This is an area of obviously
great interest. If an erythropoetin could
be made available, we might eliminate
this. Stanley Sheldon in London believes that more intense dialysis and a
higher protein diet will minimize the
anemia.
The greatest problem for the patient
is controlled hypertension. The real
cross these patients must bear is learning to eat a low-salt diet. There is no
question that if he can learn a low-salt
diet, his blood pressure will be controlled. It takes from three to six
months for a patient to really learn to
eat a low-salt diet. They cannot cheat.
If they eat salt, they gain weight, and
it shows up on the scale when they
come into the center. Once they learn
it, their pressures are controlled either
at, or near, the normal level.
The Future of Hemodialysis

With this background, then, I am
going to talk briefly about my concept
of the future of management of
chronic uremia. One point I want to
make here is about good conservative care. This is an area which is
greatly misunderstood, both by nephrologists and by doctors in general.
The most important factor we have
found in the management of the
chronic is the control of hypertension
by means of sodium restriction. All
the emphasis in the literature on the
management of the chronic has been
on the salt-losing crisis and the magic
effects that salt has on a patient in
uremia. This is not the place to put
the emphasis. There is no question
that, if a patient is salt-depleted, and
his neck veins are flat and his blood
pressure is down, that his GFR will
drop almost to zero. Salt, then, can
have a miraculous, life-saving effect on
this patient. But for every one of these,
there are 500 patients who are being
abused by too much sodium. It is our
contention that it is the high blood

pressure induced by sodium overload,
rather than the disease itself, that is
most often responsible for progression
of the renal lesion to the fatal end. And
we have diagrammed this idea by
showing the maximum and a minimum
sodium excretion for a patient having
progressive loss of his kidney function
over a 30-year period. At some point,
he gets both a floor and a ceiling on
this ability to handle sodium. The inability to conserve sodium has gotten
all the emphasis because a few patients,
particularly those with pyelonephritis
and polycystic disease, waste sodium.
But as of now in our renal clinic, we
have about 30 chronics with serum
creatinines above 2, and there is only
one that is a significant salt waster. The
more important problem is that they
have an upper limit on their ability to
excrete sodium and when they start
taking in more than they can handle,
their blood pressure rises, they get
malignant hypertension, and die. We
give every patient a blue book to record his blood pressure, weight, and
urine volume, although the urine volume is not really important. Then we
teach them the relationship between
the amount of salt they eat, the change
in their weights, and the change in
their blood pressures. We saw a patient in 1960 who had "bad hypertension". The sole maneuver there was
to put him on sodium restriction. True,
his creatinine bounded around a little.
When first started, the creatinine will
always go up, which is another thing
that has received undue emphasis. As
long as it does not go up into the
symptomatic range, you should not
care. Because, if you are not going to
control that blood pressure, experience
shows that the man will be dead in a
matter of months. Four years later,
this patient's creatinine is still stable
around 8 and his blood pressure is well
controlled on a low salt diet. Occasionally it is well to add small doses of
blocking agents, but our experience
shows that patients with uremia tolerate these drugs very poorly. If they go
into dialysis, they are going to have to
go on a low salt diet anyway. We prefer to use the diet as our major therapeutic tool. All of our patients, we
feel, would have been dead within
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months had their b!ood pressures not
been controlled. So the message is,
control blood pressure by any means
that you can , and you are likely to get
a lot more mileage out of your patient's
kidneys and avoid the day when definitive therapy is going to be needed. I am
not minimizing the importance of giving salt if the patient is sodium depleted, but this is a very special , rare
problem. What I am talking about is
the garden-variety, day-to-day management of the patient with renal insufficiency.
The Place of Peritoneal Dialysi;

Dr. Fred Bohn has been working in
peritoneal dialysis for a number of
years, and his monograph is well
known . Eighteen months ago, peritoneal dialysis in the management of the
chronic was discredited, and rightly
so, because peritonitis was the rule.
Dr. Bohn devised an automatic cycling machine; which is a completely
closed dialysate system. He figured out
an experiment to sterilize these big
bottles of fluid so that no one has to
cycle the machine, thereby eliminating the need of the nurse or family.
Now, after having lost one patient with
peritonitis, he has a second patient going, and believes it is because of this
closed system which maintains sterility.
After three months of treating this
patient for recurrent peritonitis, he
resolved that the indwelling peritoneal
access prosthesis was the villain, and
to make a successful chronic peritoneal dialysis, he had to insert a peritoneal cannula every week, through a
tiny incision that heals from one week
to the next. Since he removed the
prosthesis, he has not had a bit of
trouble with peritonitis. It is on the
basis of comparing the patient who
loses significant amounts of protein
through the peritoneal membrane with
our patient on hemodialysis, that we
think that a synthetic membrane with
a larger pore size is needed.
Hemodialysis in Relation to Transplantation

We
future
hope
There

are very concerned about the
of dialysis in relation to the real
in this field, transplantation.
is no question that if you have

a human kidney inside you, working,
this is far superior to an artificial one.
You are not tied to a machine, you
don't have to worry about getting to
the center, you don't have to take care
of cannulas, and you don't have to eat
a low salt diet. But as we see them,
here are the facts on the current status
of transplantation : Of the identical
twins whose operations were performed five years ago, 70 % are now
dead of recurrent kidney disease. The
recurrence rate is 50 % in the Boston
group. We had a patient with glomerular nephritis who was sent to the Mayo
Clinic and transplanted from her
mother. Six days after the transpl ant,
the mother's kidney was destroyed by
the same disease that originally had
destroyed the patient's kidneys. This
is a very important case, of course. A
question raised is, had this patient
been carried for two or three years
on chronic dialysis, would this immune activity have abated and would,
then, the transplanted kidney have survived? If we get another such patient,
we will try a double transplant, probably first from a cadaver, doing it right
away, and then waiting two or three
years and trying it a second time. Dr.
Don Thomas, who is in charge of our
transplant program, recently reviewed
the latest summary from Dr. Joe Murray's group in Boston. He concluded
that the chances of surviving for two
years on a transplanted kidney are
somewhere between 5 and 20 % . The
chances of surviving for four years
probably are less than 1 % .
I can say with some conviction that
the chance of surviving four years on
chronic dialysis in the current well-run
program approaches 100% . The big if
in the dialysis program is that you
must have a cooperative patient. The
one thing stressed by all now doing
chronic dialysis is, if the patient cannot cooperate, take care bf his cannulas, or stay on the low salt diet,
then the chronic dialysis is not a very
good form of treatment. The amazing
thing we have found is that a group
of patients who are cooperating seem
to pull along the ones who are not,
especially during the early days when
they are learning about the program.
Most patients will cooperate, because

when they begin to feel well and see
what salt overload does to them, they
learn from bitter experience that it is
better to cooperate than to be sick.
I want to make another point that
I believe is important because of the
neuropathy problem. Despite economics and the intense need right now,
the sooner we make a logical transition
from good pre-dialysis care into dialysis, and into transplant after dialysis
without having a crisis, the sooner our
patients are going to be happier. Our
new clinic that will be opened at Swedish Hospital has the capacity for 30
new patients. Our patients who now
are being treated in town by the various kidney doctors have already visited the center. They know what they
are going to get into when the day
comes. They have heard about transplants, they are prepared emotionally,
and they are getting prepared financially to take on the definitive treatment, long before it will be necessary.
This is an ideal that we are far from
achieving. When we do achieve it, our
patients and doctors will be much
happier.
Home Dialysis

So the hope for the future rests on
lowering the cost of the present form
of treatment (the central pumping system is one example of how we are doing this with the important cooperation
of our engineering colleagues), some
form of home dialysis, and, of course,
the big hope is that we can make real
progress in the immunology of transplantation. Now we have a very exciting development, one that I think
offers real hope, particularly in the
financial area. That is home dialysis.
Our first patient on the home program
was a young high school girl who is
dialysed by our family in her basement.
The dialyser is a miniaturized version
of our central pumping system that is
fully automated. A standard Kiil dialyser is used. We switched from zepharin
or formaldehyde to acetic acid, a more
effective germicide that is often forgotten. When using acetic acid to
sterilize the artificial kidney, some is
left in, which the patient readily metabolizes. Then, when ready to dialyze,
you simply hook the kidney to the bath
5
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source, acetic acid becomes sodium
acetate, and you convert a germicide
into a metabolizable substance. Then,
as I mentioned, the dialysis fluid is
supplied by a miniaturized version of
our central pumping system or by a
home tank.
We started the patients in an isolated
area of the hospital, where the family
can be taught a little about what goes
on inside an artificial kidney. The family first observes the technique and
gradually begins to take over. It takes
a surprisingly short time to teach a
family to operate a system at home.
We totally underrated the motivation
of the patient to learn. The family
realizes it is their relative's life at stake,
and that if they do not learn to run the
equipment, they might well lose their
relative. They learn much faster than
our technicians and nurses who train
for our center program.
We are literally just scratching the
surface on what is going to be possible
in the home program. The cost, which
we hope is generous, looks like it is
going to be under $5,000 per year. The
breakdown is very encouraging, because such things as equipment, maintenance, and depreciation are the kind
of things communities can fund. This
leaves $3,000 or so per year for the
patient to pay. The startup costs are
around $8,500 for the first year. This
is a very rough figure; we do not have
enough experience with home dialysis
to know, but at least it is less than
half of what our current center type
of operation costs. (As of November
1965, there are seven patients on home
dialysis in Seattle, and there have been
no failures.)
The advantages of home dialysis,
in addition to the cost factor, is more
intensive dialysis. It can be done in the
evening, for example. Instead of spending the evening in the center, they
spend the evening at home. When an
unattended nighttime dialysis is possible, we have 56 hours a week during
the night to dialyze. This would then
free all of the patient's waking hours
for normal activities. A very important
point psychologically, is that the patient
himself becomes responsible for the
care instead of the institution. There is
a real feeling of independence.
6

Frequent short dialyses are more
effective. On twice-weekly dialysis, for
a total of 20 hours per week, the patient's creatinine got up to 12. On
three times per week, for a total of 18
hours or less time per week, his
creatinine got up to 10. So this kind of
study projects that the frequent short
dialyses are going to keep these patients much healthier than the infrequent, prolonged dialyses can.
One problem is that not everybody
is going to be able to go home. We
estimate, in our present population
of about 20 patients in Seattle, that
only half are going to go home. There
are going to be other solutions, but
the home program is the ultimate one.
The center type is perfectly satisfactory
if you can afford it, and something in
between may be the answer for other
patients. Maybe you can get them together in an apartment home-"You
dialyze me tonight and I'll dialyze you
tomorrow night"-This sounds crazy
but it will be necessary if people are
going to survive within the economic
limits we can provide.

Recent Experience with Hemodialysis
in Acute Renal Failure, Chronic Renal Disease
with Reversible Features, and in Conjunction
with Renal Homotransplants
JOHN D. BOWER*

Department of Medicine, Medical College of Virginia, Richmond

During the past 10 years, hemodial- number of dialyses done for acute renal
failure and poisoning. There has been
ysis has progressed from a dangerous
procedure requiring one or more phyno dialysis done for the maintainance
sicians in constant attendance, to a
of life in chronic uremia. The purpose
safe nurse-technician activity. Simiof this paper is to give a brief resume
larly, the indications for initiating diof the development of the artificial
kidney unit at MCV, and to report on
alytic therapy have changed as the
the results of its use.
procedure has been simplified and
It has been less than 15 years since
made almost completely innocuous. It
MCV acquired its first artificial kidney
is now felt that one should not wait
machine. This cumbersome and comfor the patient to develop advanced
plicated monster was referred to affecuremia before placing him on the
tionately as the "rotating drum." It
artificial kidney, but instead one should
required several physicians to operate
use this newer method of treatment
it but it did give all those involved
before the complications of uremia set
with its operation considerable confiin. But dialysis should not be looked
dence and encouragement that dialysis
upon as a substitute for good medical
did work. The next machine that was
management; on the contrary, prepurchased was the twin coil kidney.
dialytic management is more important
This instrument greatly simplified the
now than ever. The most important
procedure of dialysis and aroused the
use for dialysis remains in acute renal
interest of many workers in the field
failure. More recently, however, it has
both at MCV and throughout the
been used for the maintainance of
world. The greatest burst of enthusilife in chronic uremia (Pendras and
asm for dialysis at MCV occurred in
Drickson, 1965; Gombos et al., 1964),
the fall of 1962 when it was decided
the treatment of many cases of poisonto undertake studies in renal homoing (Maher and Schreiner, 1965) and
transplantation in man. The dialysis
to support renal homotransplantation
facilities at that time consisted of the
(Bower and Magee, 1964).
twin coil machine and peritoneal lavAt the Medical College of Virginia
age. This latter method of dialysis
(MCV) the great majority of dialyses
had recently enjoyed a rejuvenation
have been done in conjunction with
with the appearance on the market of
the transplant program now under way
commercially available prepackaged
(Hume et al., 1964). In addition, there
sterile peritoneal dialysis fluid.
has been a significant increase in the
It soon became apparent that both
of these methods of dialysis could not
* Now in the department of medicine,
meet the demands of the transplant
University of Mississippi, Jackson.

program. For this reason, in January
of 1963, the hospital purchased its
first Kiil kidney (Kiil, 1960). This
machine was designed originally to
replace the human kidney during acute
renal failure. Later it was found to be
well suited for the maintainance of
life in chronic uremia and it is today
used in the majority of successful
chronic dialysis programs. After few
modifications it was found that it was
likewise made suitable for supporting
a transplant program. The next major
advance in the dialysis program at
MCV again grew out of necessity.
The kidneys were being operated in
several different areas of the hospital,
inefficiently. It became apparent that
larger and more permanent quarters
. were needed to meet the ever-increasing demands of the transplant program
as well as the increasing volume of
acute dialysis. In the fall of 1964, the
present dialysis unit was completed on
4 North of the main hospital building
and 10 Kiil dialyzers were located in
this area. This space consisted of approximately 1100 square feet divided
so that there would be a supporting
laboratory and a patient dialysis area.
As many as 6 dialyses can be done
simultaneously in this area, with facilities available for dialysis at all
times.
Method of Dialysis

Each candidate for dialysis has a
silastic tef!on shunt (fig. 1) inserted
7
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Fig. 1.-Arterio-venous shunt worn by patients that are on repeated dialysis.

Fig. 2.-The Kiil Artificial Kidney showing the two blood inlets at the middle of
the right end and the singly larger bath outlet. The Harvard pump on the second
shelf is used to infuse heparin to prevent blood clotting inside the artificial kidney.
8
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under local anesthesia in a small peripheral artery and vein. When the
patient is not on the artificial kidney,
blood is allowed to flow from the artery
into the vein to maintain a constant
flow of blood, thereby preventing clot
formation. This mechanically exteriorized A-V fistula has not been known
to produce cardiac decompensation
and it does avoid the need for repeated cutdowns. Before this technique
was devised the number of dialyses that
could be done in any one patient was
limited .
The dialyzer itself (fig. 2) is quite
simple in design and function. Its sole
purpose is to create a large surface
area with a minimum volume of blood
out of the patient in contact with the
bath sol ution on the other side of the
cellophane membrane. The bath solution consists of a physiologically balanced electrolyte solution plus glucose
to adjust the osmolarity. The volume
of blood necessary to fill the dialyzer
and thereby give 0.9 M ' of dialyzing
surface is only 350 ml. This small
volume eliminates the necessity of
transfusions when using the Kiil dialyzer. When the patient is placed on
dialysis, the A-V shunt is crossclamped and the continuity of the
shunt disrupted. The arterial line of
the shunt is connected to the dialyzer
inlet and the patient is bled into the
dialyzer, replacing the heparinized saline and filling the dialyzer blood compartment. When blood begins to appear
in the dialyzer outlet line, it is connected to the venous side of the shunt.
Blood then flows continuously from the
patient through the dialyzer and back to
the patient. At the end of the procedure, the blood in the dialyzer is
returned to the patient by flushing it
back in with saline. The net loss of
blood per dialysis is 30 to 50 ml. Blood
pumping is not necessary, but it is done
in some centers to speed up the rate of
dialysis and reduce the time spent on
the kidney. Without blood pumping,
it usually requires two 12 hour periods
of dialysis per week to maintain an
anephric patient asymptomatic of
uremia. The rate of blood flow through
the dialyzer without pumping is approximately 100 to 150 ml per minute.
The bath solution flows at the rate of

approximately 500 ml per minute and
is then discarded. By running the bath
solution through the dialyzer only once
and then discarding it, several patients
can be run from a single bath source,
providing they can all tolerate the same
bath composition. This entire procedure is executed by especially trained
nurses and technicians, thereby freeing
the physician completely. The major
role of the physician in a dialysis
center is to care for the patients off
dialysis, and to decide when dialysis
should be carried out. The physician
must also occasionally modify the
bath formula as deemed necessary according to the patient's individual
needs. There is no reason to feel that
any physician who h as taken the
time to make himself aware of the
benefits of dialysis and what can be
expected of the procedure, should not
be able to order this service when indicated.

TABLE 1

Hemodialysis with Transplantation

Average
Number dialyses
per
of
Dialyses transplant
Pre-transplant
Post-transplant
<2 weeks
Post-transplant
>2 weeks
Patient
never
transplanted
Patients awaiting
transplant
Total

614
39

11.6
2.6

30

6.0

61

5.5

16

4.0

760

Results and Discussion

Dialysis with Transplants
During 1962, 15 dialysis were done.
Six of these were done in conjunction
with the transplant program on 3 patients and the remaining 9 were for
acute tubular necrosis and barbituate
intoxication on 6 patients. In 1963 ,
there were 195 dialysis done, and in
1964, 507. The great majority of the
dialyses in 1963 and 1964 were for
the transplant program, using primarily
the Kiil kidney.
Between August 1962 and April
1965, 63 renal homotransplants were
carried out in 57 patients. Four patients were transplanted twice and one
patient had 3 transplants. In order to
support this program, 760 hemodialyses were done. The distribution of these
dialyses is shown in Table 1.
Most pertinent to this discussion are
the data on patients that were never
transplanted. These 61 dialyses were
done in 11 patients, all of whom are
now dead. Five of the first ten admissions to the transplant program died
before they could be transplanted. We
attribute this to inadequate dialysis
facilities. Peritoneal dialysis was used
in four of these five patients and these
four had significant peritonitis that
9
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contributed to their demise in uremia.
For this reason, it is felt that peritoneal
dialysis is not adequate to support a
transplant program. The remaining 6
deaths occurred evenly distributed over
the subsequent 58 admissions. Therefore , by instituting an active dialysis
program, the mortality rate prior to
transplantation was reduced from 50 %
to 10.3 % . Looking now at the six
deaths that occurred after dialysis facilities were adequate, we find that one
of these was preventable. This occurred in a six year old male who was
being dialyzed for the first time. He
was in congestive heart failure and was
receiving digitalis. When his serum potassium was lowered by the artificial
kidney to normal levels he developed
digitalis intoxication and died of ventricular fibrillation. The remaining five
deaths pre-transplant were attributable
to septicemia in two, brain stem hemorrhage in one, and gastrointestinal
hemorrhage in one. One patient refused further dialysis and transplantation .

Dialysis for Acute Renal Failure,
Chronic Renal Disease and Poisoning
Since the development of our existing artificial kidney unit, the volume
of acute dialysis has likewise increased .
As stated earlier in 1962 only 6 patients other than transplant patients
received dialysis. This number increased to 9 in 1963 and 15 in 1964.
The 24 patients that were dialyzed
between Jan. 1, 1963, and Dec. 31 ,
1964 are divided into three groups.
The first group was made up of eleven
patients who had acute renal failure
with otherwise normal kidneys (table
2). The second group, comprising 10
patients, included those with known
chronic renal disease, but with superimposed reversible features (table 3).
The third group consisted of three patients with attempted suicide, who were
dialyzed to remove the ingested toxin
(table 4).
The results of dialysis are most rewarding in acute renal failure. In our
own series of eleven patients, seven regained sufficient function to bring
their BUN and creatinine back to normal , and in five of these that were
10

TABLE 2

Dialysis for Acute Renal Failure

Patient

Number
of
Dialyses ·

Etiology

Results t

--

1

K .S.

2
3
4

J.C.
C.H.
Z.T.
R.J .
C.B.
G .S.

5
6
7

w.c.

8
9
10
11

J.B.
J .R.
M.B .

f
l

Cortical Necrosis ,
Post-partum Hemorrhage
A.T .N .*, Gunshot
A .T .N ., Septicemia
A .T.N., Septicemia
A.T .N., Abruptio
A .T .N., CCl 4
A .T .N ., Pancreatitis
A.T.N ., Ethylene glycol
A .T.N ., Septicemia
Acute Vasculitis
A.T .N., Hemorrhage

14
3
3
5
1
2
1
4
6
2
2

Transplanted ,
Died.
B
A
A
A
A
B
A
Died
Died
Died

* A.T.N.- Acute Tubular Necrosis ;t Classification of results : A, GFR > 75 cc/
min, B , patient alive BUN and creatinine normal, but no evaluation ofG .F.R. available .

TABLE 3

Dialysis for Chronic Renal Disease with Reversible Features

Etiology of Acute failure

Number
of
Dialyses

Results*

Iatrogenic Acidosis
Pyelonephritis
Accelerated Hypertension
Pyelonephritis
Pyelonephritis
Pyelonephritis
Dehydration
Pyelonephritis
Pyelonephritis, A.T .N .
Heart failure due to rheumatic disease

1
1
6
4
3
2
2
4
1
2

Lived 6 months
Lived 2 weeks
Lived 1 week
Transplanted , Died
Lived 2 months
Lived 3 weeks
Lived 3 weeks
Lived 1 month
Lived 1 day
Lived 1 month

Patient
-

--

1
2
3
4
5

6
7

8
9
10

E.D.
J.W.
J.P .
B.C.
S.C .
E.L.
R.D.
A.S.
A .C.
N .J .

* Duration of life after last dialysis .

TABLE 4

Dialysis for Attempted Suicide and Intoxications

1
2

3

Patient

Drug or Toxin

E.S.
W.G .
J.C .

Combination of Drugs
Barbiturates
CCI•

Number
of
Dialyses

Results

Living and well
Living and well
Died

J. D. BOWER
checked with creatinine clearance
studies, all were found to have a clearance of greater than 75 ml per minute.
There were four deaths in this group.
Of these, two were probably not dialyzed long enough or frequently
enough, as borne out by the fact that
they died in uremia. One patient (J.R.)
with an acute vasculitis of unknown
etiology died with azotemia of a significant degree, but it is not felt that
renal failure was the cause of death.
The fourth death occurred in a patient with renal cortical necrosis following a complicated delivery. The
patient was maintained on the artificial
kidney for eight weeks. At the end of
this period, an open biopsy of the kidney revealed cortical necrosis. The patient was then bilaterally nephrectomized and transplanted.
In our present state of knowledge,
it appears that the prognosis for a
patient living through an episode of
acute tubular necrosis is more dependent on the prognosis of the underlying
disease than on the tubular necrosis itself. In our own experience, we have
maintained a bilaterally nephrectomized patient on dialysis in a reasonable state of good health for over 14
months. Scribner et al. now have some
essentially anephric patients that are
doing quite well after 5 years on dialysis.
In those patients with chronic renal
disease who suddenly become decompensated due to a superimposed acute
insult, the results are not as good. Here
again the prognosis is determined by
the underlying chronic renal disease
and the availability of chronic dialysis
facilities.
Dialysis is very useful in the management of drug intoxication and attempted suicides. First, it promptly
removes the offending agent from the
blood, and secondly, it shortens the
period of unconsciousness, thereby
reducing the complications of coma.

for acute exacerbations superimposed
on chronic renal insufficiency. The
great majority of dialysis at MCV
has been done in conjunction with the
ongoing renal homotransplantation
program. Here dialysis has proven to
be an innocuous procedure and has
contributed significantly to the success of this program.
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Summary
Hemodialysis is a safe acceptable
method of treatment for drug intoxication, and acute renal failure. It is
also useful in the management of patients with chronic renal disease either
on a periodic basis or, intermittantly,
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Dr. David M. Hume (Stuart McGuire Professor, and chairman, department of surgery, Medical College
of Virginia, Richmond): I'd like to begin by asking Dr. Doolan a question.
Do you have any special technique or
criterion, Dr. Doolan, for determining
the reversibility of disease in a patient that is being dialyzed for acute
renal shutdown? That is to say, how
do you decide whether to turn the
dialysis off after several days?
Dr. Paul D. Doolan (director, clinical investigation department, Naval
Medical Research Institute, Bethesda,
Maryland): I don't know if I understand this question.
Dr. Hume: Well, suppose you've got
a patient with acute shutdown and you
have dialyzed him, because you had to
keep him going. How do you decide
whether this patient is going to "open
up" sometime on his own; how long
do you keep dialyzing him if you don't
have a chronic program, and when do
you decide that the shutdown is irreversible?
Dr. Doolan: If he's got acute renal
failure, I don't know whether you can
ever say it's irreversible. This question
seems to emerge when you have shutdowns of unknown origin, and you
are wondering about whether the person doesn't have acute glomerulonephritis, for example. If they don't open
up in less than 30 days, then the likelihood of their opening up is very remote.
Dr. Hume: How do you decide they
have got acute glomerulonephritis?
Dr. Doolan: Well, I think history
and clinical appraisal is all I know of.
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If an adult is shutdown with acute
glomerulonephritis, the prognosis is
poor. I think it varies among different
people as to when you feel justified in
doing renal biopsy to see whether or
not this will help you with making the
decision of whether to continue dialysis. I would say that, in my own experience, renal biopsies have not
helped.
Dr. Hume: Anybody else on the
panel want to comment on this question?
Dr. John E. Kiley (professor of
medicine, Albany Medical College,
Albany, New York): I think when you
see a patient with acute renal failure
that does not open up after two or
three weeks, you begin to see a somewhat characteristic behavior on the
part of the physician handling the case.
What we tend to do, first, is to support
the patient by dialytic means, hoping
that diuresis will ensue. But once you
go into the second or third week, one
certainly begins to feel pushed. After
having eliminated any obstructive
uropathy (by cystoscopic examination,
etc.), we then do a renal biopsy. And,
although there are some contraindications to doing a biopsy, it has been
helpful in revealing a disease condition that we had not suspected, e.g.,
glomerulonephritis, overwhelming pyelonephritis, and infarction of the kidney. These conditions tend to make
one turn off the dialyzer, because this
is not acute tubular necrosis, and the
kidney will not regenerate. The other
thing to do would be to put a catheter
up by way of the femoral artery to the
level of the renal artery and inject a
radioopaque dye. In this way, one can
study the vascularity of the kidney. In
some instances we have discovered
that there has been bilateral infarction
which we didn't suspect. This usually
occurs when the patient has infarcted
one kidney, say a year or two earlier,
without its being clearly diagnosed,
and later the patient has infarcted the
other kidney. So, renal biopsy and
pyelography can be helpful, when, after a month of dialysis you're beginning
to wonder whether you are not rapidly
going into chronic dialysis, inadvertently. Perhaps someone else on the
panel has had more experience than

I with the use of the newer diagnostic
techniques of infusion pyelography.
Dr. Hume: Some patients don't
"open up" for 60 days. The question
is, at the end of 30 days, what do you
do?
Dr. Belding H . Scribner (chief, division of kidney disease, department
of medicine, University of Washington,
Seattle): We're obviously confronted
with this problem continually, because
we do have a chronic program that is
full. But at the same time, we are in
a very serious dilemma in this kind
of situation. I underscore completely
what John Kiley says about the use
of the biopsy at the 30-day point, so
to speak. The other side of the coin
here is, if you do find normal glomeruli
and tubular necrosis at 30 days, then
you are committed to keep the patient
going on dialysis indefinitely. I know
of one patient from Stanley Sheldon's
group in England that went 90 days
with tubular necrosis and then opened
up. So, on the hopeful side, if you do
come up with this diagnosis on renal
biopsy, even in the presence of anuria,
then you are obliged to go on. If you
are worried about the vasculature, I
think the aortogram may be done in
60 days or 90 days, if you are still
"sitting" on the case. I can not elucidate the question Dr. Kiley raised
about the newer radiographic techniques.
Dr. Joseph H. Magee (director of
renal section, department of medicine,
Medical College of Virginia)'. I want
to allude to what Dr. Scribner just
said. One of the abstracting journals
had reported two cases of cortical infarction, where dialysis was carried
out for 70 to 80 days before recovery.
The authors believed that some onesixth or one-fifth of nephrons, which
are juxtamedullary, will come back
and function if you dialyze them long
enough. So I wonder if you aren't on
the griddle for about two to three
months, where shock or cortical infarction might have been the cause of
shutdown.

' At present, assistant professor of
medicine, Jefferson Medical College,
Philadelphia.

Dr. Hume: Would anybody on the
panel like to tell about his experience
with the use of large quantities of
contrast material, or would anybody
like to comment on the use of radioactive materials, renal scans or radiorenograms, as assists in determining
whether renal artery thrombosis has
occurred-Dr. Kiley?
Dr. Kiley: Well, of course, I can't
see how the use of radioactive substances is going to help you, because
they don't really reflect the blood flow ,
but rather the ability of the tubular
cells to concentrate and excrete the
isotope. These patients may have
neither blood flow nor secreting cells,
so I would not be enthusiastic about
these procedures.
Dr. Hume: If you have neither
blood flow nor kidney cells, you
wouldn't get any uptake, but if you
have got some uptake, then that would
be some evidence of vascularity.
Dr. Kiley: If you're looking for
vascularity, I still think that renal
angiography would be beter than isotopes.
Dr. Hume: Dr. Kiley, in your earlier
discussion (paper on artificial dialysis
in adults), you talked about using dialysis for hypercalcemia. I am wondering if you would advocate this form of
therapy in hypercalcemic crisis, rather
than operating on a patient who has
hyperparathyroidism and hypercalcemic crisis, and removing his parathyroid adenoma. Another condition
I noticed on your list was ammonia intoxication, and I wonder how your
results have been with this.
Dr. Kiley: Well, first, I'll put my
guard up by saying that at that time I
was showing a list of situations which
have been recorded as successfully
treated by dialysis. Now, with hypercalcemia, we have an interesting situation there. I have not personally treated
a hypercalcemic crisis by dialysis, so
I am in no position to disagree with
Dr. G lenn's2 statement that parathyroidectomy is preferable. However, as

2 Dr. James F. Glenn, professor and
chairman, department of urologic surgery,
Duke University, bad spoken earlier on
surgery in the prevention of uremia.
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a surgeon, I would like to strike back
by asking you if this would not be an
extremely difficult type of emergency
operation. The hypercalcemia may be
due to hyperactivity of the parathyroid,
which is deeply situated within the
body. I think the complexity and difficulty of this surgery is at least a factor
suggesting that dialytic therapy might
be more efficacious; it is certainly more
straightforward. How do you feel
about this operation itself?
Dr. Hume: We have not had much
experience with this. We had one patient who we thought had this problem.
He certainly had a hypercalcemic
crisis, and we dialyzed him for a
short while, with some fall in calcium,
although its level did not fall strikingly.
We then took the patient to the operating room, explored the neck and then
made the diagnosis of widespread
metastatic disease, which hadn't shown
up in x-rays. The patient ultimately
died of malignant disease. Dr. Magee,
do you recall that patient? I've forgotten exactly what the results of dialysis were.
Dr. Magee: I think we got calcium
down from about 20 to 18. We just
dialyzed for minimum number of
hours and weren't getting anywhere
and proceded with the operation.
Thomas and co-workers 3 in a review of
about 14 such cases, said they believed
the thing to do was to get them right
up to the operating table, because you
just can't dialyze fast enough.
Dr. Kiley: Well, I would disagree
with that. I think that if you are equating a good operation with relatively
poor therapy, that certainly is true,
but I also think that there are better
medical ways of managing this disorder than by dialysis. As a matter of
fact, I think dialysis may be weak,
because you are dealing with a double
equilibrium caused by abnormal parathyroid hormone, so you will have
calcium coming out of the skeleton
just about as rapidly as you can dialyze
it out. On the other hand, by the use

3 Thomas, W. C., Jr., J. G. Wiswell,
T. B. Connor, and J. E. Howard. Hypercalcemic crisis due to hyperparathyroidism. Am. J. Med. 24: 229-239, 1958.
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of sulphate and citrate, and, at least
theoretically, EDTA, you can cut down
considerably on the amount of ionized
calcium that is present. This kind of
medical therapy, although a temporary
measure, can give you a good deal of
time, even in the middle of the night,
to prepare the patient and the operating room for surgery. And it can forestall the disaster that sometimes occurs
with sudden death. So, I wouldn't minimize the usefulness of the right kind of
medical therapy.
Dr. Doolan: I don't know whether it
was a tribute to Dr. Kyle, my old boss,
but I never saw a hypercalcemic crisis
with hyperparathyroidism, and he had
only a few cases. I have seen hypercalcemic crises with metastatic bone disease. This is the case in which you are
not worried about operating. You can
lower calcium by giving these people
steroids, or you can lower it by doing
peritoneal lavage, and, if you want
to, you can put EDTA in the peritoneal lavage solution and remove even
more calcium that way.
Dr. Hume: That's a good thought.
Actually, there have been about 40 of
these reported in the literature and
the mortality is about 50 %.
Dr. Doolan: With the hyperparathyroid?
Dr. Doolan: Yes.
Dr. Magee: And there are a lot more
now.
Dr. Doolan: Well, my only point
was, they're not all surgical.
Dr. Hume: No, not right away. We
get them in the end, though, because
there is no medical cure for hyperparathyroidism.
Dr. Doolan: The discussion has
spun around how fast the patient with
hypercalcemia should get to the operating room. But, what about the
hypercalcemia that is not due to hyperparathyroid?
Dr. Hume: Well, we don't take those
to the operating room.
Dr. Doolan: This is why I mentioned
peritoneal lavage, steroids, and EDTA
in the peritoneal lavage solution.
Dr. Hume: It is true that the majority of the hypercalcemic crises that
we have seen here have been due to
carcinoma of the breast, and we usually treat those with steroids to get

them off the hook. Now, Dr. Kiley, I
would like to ask you about dialysis
in ammonia intoxication.
Dr. Kiley : We demonstrated quite a
few years ago that the ammonia ion
is very efficiently removed by a dialyzer, and we have used this with some
gratifying results in about half a dozen
patients. The thing I want to emphasize is that I don't believe at all that
this is effective clinical use of dialysis.
Ammonia toxication is almost invariably handled better by other approaches.
Dr. Hume: Were these people in
hepatic coma, or were they people who
had ingested some household detergent?
Dr. Kiley: The patients who were
successfully treated were patients with
portal cirrhosis who were getting along
quite well, who then had a massive
gastrointestinal hemorrhage. The hemorrhage was then stopped one way
or another, but they went into ammonia intoxication from digestion of
the blood in the gastrointestinal tract,
and they were benefited by the removal
of this excess ammonia. But I think
this has very little practical general
clinical worth.
Dr. Hume: Dr. Kiley, when I was
an intern and resident, we used to see
patients with various types of renal
shutdown and potassium intoxication.
In those days, a major indication for
dialyzing a patient was potassium intoxication. We used to go scurrying
around trying to get the patient just
on the razor's edge, watching for EKG
changes of potassium intoxication. And
we were in sort of a sweat to see
whether he was going to survive, and
to judge the right moment to put him
on the kidney. Now you suggest in
your talk that we ought to get an EEG
instead of an EKG, to decide when to
put the patient on the kidney. This is
harder to get than an EKG, and it is
somewhat more difficult to interpret.
Do you really feel that this is the way
to decide when to put a patient on the
kidney?
Dr. Kiley: Well, first of all, let us be
clear that the EEG has nothing to do
with potassium intoxication. Although
I was possibly skipping along to catch
up a little time, I did preface my slide
of the EEG with the statement that
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it was not generally available. And I
would agree with your comment that,
were this to be efficiently used, it must
become more available clinically, and
I think we must work more to that end.
We have it fairly available now because this is a particular interest of
ours. We have a portable EEG machine which can be taken to the ward,
and you can count the frequency of
the waves per second as they come off
the machine. So, the EEG can become
clinically useful, and I think it is
something we must progress with.
Really, what we are striving for here
is a relatively simple electronic counter
which will sort the seconds into two
stacks; those in which the wave frequency of the EEG is above six and
those in which the wave frequency is
below six. The latter is a clearly abnormal situation. I do think that all
of us are now using the EKG for potassium intoxication, particularly since
the cardioscope has become generally
available. If we have a potassium problem, we move the cardioscope into
the room and turn it on and monitor
the EKG continuously.
Dr. Hume: I was wondering, since
Dr. Scribner has demonstrated that
dialysis is so easy to do in the basement, why don't you simply dialyze the
patients repeatedly when they have
uremia, rather than rely on some particular danger signal to put them on
dialysis?
Dr. Kiley: I think you're quite right,
and I think that this is where we should
be going. And, we should be using
the artificial kidney and other dialyzers
more as the human kidney, to preserve
normalcy, rather than to correct a very
abnormal situation. But I think that, in
the present state of our knowledge, the
main question is just how much dialysis is ideal. We just don't know that,
because we have not yet correlated the
changes in metabolism, particularly
nitrogen metabolism, with these physiological changes. The thing I like
about the EEG is that for the first time,
we have something reasonably objective in altered physiology which we can
use in clinical uremia. I was all sort of
up-in-the-air in clinical uremia because
we usually stood at the foot of the
bed and looked at the patient, and

wondered how sick he was, and that is
hard to go on.
Dr. Hume: Dr. Finberg, I wonder if
in the course of dialysis for poisons of
one sort or another you ever see a rebound phenomenon after the dialysis
is done. That is, the patient wakes up
from dialysis and then, sometime later,
he lapses back into coma. Has this
ever been a problem?
Dr. Laurence Finberg (chief, division of pediatrics, Montefiore Hospital, and professor of pediatrics, Albert Einstein College of Medicine, New
York): In most of the common poisonings that we see that is not a problem.
There are some poisonings in which
that has been notoriously reported to
be the case. Then, you have to go back
and dialyze again.
Dr. Hume: Dr. Finberg, supposing
you have a problem, as occasionally
comes up, that a child is born without
kidney function. Is there any effective
way to dialyze the newborn baby, or
otherwise to manage the problem?
Dr. Finberg: Yes, I think there are
two comments pertinent to this question. One is that the infant is probably
the only living organism that can survive without any renal function at all,
and without any artificial aid, for long
periods of time. The record is up to six
weeks. This is because the infant is so
rapidly growing that if the absence of
urine formation is not a consequence
of some kind of disease which in itself
induces katabolism, he will grow, and
will so expand his body fluid compartments that they can actually hold the
toxic substances in them in so dilute
a form as to permit growth. This will
be true if the infant is on the proper
feed, and the ideal feed for this is
human-breast milk. And that is how
the record was set. The mother took
her baby home, who subsequently
turned out to have no renal mass at
all. She didn't bring him to the hospital, not thinking it was terribly important that be hadn't put out any
urine, until he was almost six weeks
old. As for dialysis in infants, you can
dialyze small infants if they have an
abdominal cavity that is approachable.
You can do it with peritoneal dialysis,
of course, and this is what we talked
about before. I am told the McNeal-

Collins kidney can be adapted for
small infants, but I haven't actually
seen it in action myself. The other,
larger devices are almost impossible to
use on a small infant, even with trying
to cut down the coil area and exteriorized blood volume.
Dr. Hume: Has anybody on the
panel dialyzed a child under two years
of age?
Dr. Scribner: Dr. Robert Hickman,
in the department of pediatrics in Seattle, has been working on the problem.
It seems to me the number-one requirement for infant dialysis is a small
stable external circuit. I think Dr.
Hickman has dialyzed a child only
four weeks old, and he is using the Kiil
half-length, one-layer unit, with a completely rigid external circuit, and no
blood pumps. It is about a quarter the
size of the unit we use for adults. If
you fully prime the external circuit,
the infant's vasculature cannot tell
when he is on or off the dialyzer. The
big problem in dialysis is to shift the
blood from the equipment to the small
child and back again. With a small
rigid external circuit, we've had good
luck in infant dialysis.
Dr. Hume: Do you put the child
on a set of scales to be sure how much
weight he is gaining or losing?
Dr. Scribner: It isn't necessary unless you're filtering large amounts of
salt solution and then, of course, it's
very helpful to have him on a scale. As
far as the blood shift is concerned, if
you have a rigid external circuit that is
small and fully primed, there's no
problem with bloodshift.
Dr. Hume: Dr. Magee, I wonder if
you want to comment on some of the
things Dr. Scribner has mentioned
briefly, that is, the medical management of a patient with chronic uremia
who is not yet ready for dialysis?
Dr. Magee: Picking out some of the
things the speakers have brought up
today, the common situation now is
that practically no uremic patient
comes in on the ward about whom
you are not asked whether there is
some reversible feature. Twenty-five
years ago there were no nephrologists
because there was nothing for them to
do. Most people didn't believe for 100
years after Bright's description of
15
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uremia that there was any such thing
as reversible uremia. The things that
seem to have come along to have
changed all this were: 1) Weiss and
Parker' showed that pyelonephritis was
a common cause of chronic uremia.
They picked out, retrospectively, a lot
of reversible cases that came in with
a pericardia! friction rub or uremic
frost, and then left the hospital. Some
of the older physicians didn't think
they'd ever seen this but here there were
some cases. 2) The salt-losing nephritis
emphasized by Thorne and colleagues';
when the patients went into shock,
instead of giving them adrenocortical
hormones you only had to give salt.
3) Then along came the exponential
growth of blood banks and non-exponential growth of technicians and we
had a large number of transfusion reactions. A lot of younger fellows really
got going from the encouraging experience of bringing some of these
patients through. These easy ones are
not seen any more, but they just reinforced the concept of reversible uremia. 4) W. J. Kolff's book, New Ways
of Treating Uremia," which had the
artificial kidney in it, but most importantly, it had the high-caloric, lowprotein feedings and the protein-sparing feeding, and the necessity of
restricting water, to avoid pulmonary
edema. 5) And then came the electrocardiogram and the flame photometer,
which helped tell us when the potassium is elevated.
Dr. Hume: I would like to make a
couple of comments relative to Dr.
Scribner's talk comparing chronic dialysis and transplantation, and then
ask him to comment on my remarks.
In the first place, I think we all ought
to admit right off the bat that some
form of chronic dialysis is essential

' Weiss, S., and F . Parker, Jr. Pyelonephritis: its relation to vascular lesions
and to arterial hypertension. Medicine 18:
221-315, 1939.
' Thom, G . W., G. F. Koepf, and M.
Clinton, Jr. Renal failure simulating
adrenocortical insufficiency. New Engl.
I . M ed. 231 : 76-85, 1944.
• Kolff, W. J . New Ways of Treating
Uremia . London: J. and A. Churchill,

Ltd.
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to any transplant program. That is,
without Dr. Scribner's help, and without the use of his device, our own
program might never have gotten off
the ground. Secondly, transplantation
is not a therapeutic program at the
present time; it is an investigative program. It's difficult to talk to Dr. Scribner without being challenged by him,
because he regards chronic dialysis as
a therapeutic program. This immediately puts you on the defensive. So,
I'd like to point out the insufficiencies
of chronic dialysis, and correct a few
figures that have been given about
transplantation . 1) The patients who
were cared for by him for chronic
dialysis were a highly select group of
intelligent people. It is not everybody
who can go down in his basement and
dialyze himself. At least % of the patients we have done transplants on,
not only couldn't dialyze themselves,
they barely had the intelligence to void!
Our overall objective has not been to
see what percentage of survival we
can get, but what we can learn about
transplantation. 2) Chronic dialysis is
pretty much out with respect to children because it does interfere with
growth and sexual maturity, as Dr.
Scribner has said. 3) The number of
patients who can be benefited by
chronic dialysis is very small. Suppose
for a moment that you were to take
the point of view that the present
objective of either of these two methods is to keep the greatest number of
people alive. (Although this is not the
point of view that we take, it is the
point of view that Dr. Scribner takes.)
In his own setup in Seattle, Washington, he has had six patients on hemodialysis in a five-year period; five of the
six patients are still living. He's done
six patients on peritoneal dialysis ; five
of these patients are still living. And
he's got two patients in their basements. That's a total of 12 patients in
five years, who are living who would
otherwise have died. Our own program
of transplantation has been going only
two years. We have 28 patients living
who would otherwise have died. None
of Dr. Scribner's patients is cured ; they
all still have their disease. None of his
patients is really well, but this is not
true of any of the transplant patients

either. 4) Hypertension does occur in
patients with chronic renal disease,
even in those on a low-salt diet. We
have seen this in two instances out of
the 50 patients we've had on chronic
dialysis. Dr. Scribner hasn't seen it in
his six patients, but it does occur, and
it is a problem and one that you cannot solve with dialysis but you can
solve with transplantation. 5) The degrees of independence of the two type~
of patients, that is, the patient with
kidney transplant and the patient on
dialysis, are quite different. Even if
dialysis is done in the basement, and
even if you can dialyze yourself at
night while you sleep, it does encroach
upon your independence to a greater
extent than does the normally functioning kidney transplant in a well patient.
6) None of the patients on chronic dialysis really ever regain their pre-sickness weight. They do regain some
weight, but they never are as healthy
as the patients with good transplants,
although not all patients with transplants have good ones. 7) Almost all of
the patients on chronic dialysis require blood transfusions which are
expensive and dangerous. 8) Neuropathy is almost never corrected by
chronic dialysis-hemodialysis, that is.
9) The mortality figures are somewhat
misleading. If you take Dr. Scribner's
figures and show them on a slide today,
71 % of the patients on chronic dialysis
are now surviving. This figure is not
too different from the figure for the
larger series of transplant patients.
Sixty-two per cent of all the patients
we have done from the very first one
are surviving. Of all transplants from
related donors in the three largest
groups in the country, 73 % are surviving. Of our own cadaver transplants,
70 % are surviving; and if we took only
our last eight months' cases-93 % of
those are surviving. Even if we took all
the patients we did in the first year,
all of whom are now one or two years
post-transplant, 46 % are still living.
Four of the first six patients we did are
still living, and the two that died, died
of total body radiation, which we no
longer use. Virtually all of our patients
have been on chronic dialysis before
transplantation, ana au or mem preter
the transplant to chronic dialysis. The
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figures which Dr. Scribner quoted , i.e. ,
that 70 % of identical twins who could
have lived five years had died of the
disease of the host, are figures that
were reproduced in a recent editorial,'
and are incorrect. The facts are 80%
of all twins done in the last 10 years
are living at present. Although it has
been reported that occasionally either
the twin kidney or a hornografted
kidney has developed the disease of the
host, this has not happened as a rule,
and it has not happened in any of our
hornotransplants or any of those in
Denver. There's something more than
100 cases in this combined series, so,
I think it must be extremely rare. He
quoted Dr. Don Thomas' thoughts,
namely, that he figures that 5 to 20%
of patients who were transplanted had
a chance of living two years, and that
Jess one percent of them had a chance
of living for four years. Dr. Thomas
has recently moved to Seattle and it
is understandable that he would have
these thoughts. Dr. Scribner is a very
convincing fellow. Had Dr. Thomas
thought otherwise he might be carried
away in the middle of the night. The
actual figures from the largest series
in the country are that, of those patients who could have lived from one
to two years, 40 to 45 % are living.
Of our own patients who could have
lived for two years, which is a very
small group, 50 % are still living. Dr.
Scribner also says that the dialysis program works without doctors. But the
patient w.ith basement kidney must
have about $1,500 a year in professional fees. Furthermore, in our own
dialysis unit, which is modeled after
Dr. Scribner's, Dr. Bower hasn't had
a vacation in a year. Even though our
program is run by nurses and technicians, Dr. Bower doesn't leave town
for any length of time. I would like to
conclude these remarks by saying there
is really no competition between
chronic dialysis and transplantation because the goals of the two are vastly
different. But, I think if there is going

7 Elkinton, T. Russell. Moral problems
in the use of borrowed organs. artificial
and transplanted. Annals int. Med . 60:

309-313, 1964.

to be an ultimate solution to the problem, that the patient with a normally
functioning kidney, urinating in a normal fashion, with a completely normal
life, who feels perfectly well, and has
regained his pre-sickness weight, is in
a little better situation than the fellow
with a home kidney in the basement.
Dr. Scribner, would you like to comment on this?
Dr. Scribner: I guess we could stay
around a couple of hours and really
have at it, but time is over already.
I'll just make one or two brief remarks. We only had 12 patients at the
University of Washington because it
was not our job to take all the patients
that could come our way. Our job was
to demonstrate the feasibility of the
method, to get on with the job of doing research to improve the method ,
and to learn all we could about the
biochemistry of what's going on. Actually, unless we have had a new research project, such as the home program, we have not added a patient to
our program in over two years. In contrast, of course, the new center downtown now carries 13 patients and is
about to go up to 30, so the statement
that there are fewer patients being
benefited by chronic dialysis is simply
a function of economics. If we had the
money, we could take everybody in
King County and we think we are
going to be able to do this soon with
the combination of the center and the
home program. One or two other
points. To say that 80 % of all twins
done are now alive is not necessarily
contradicting the statement that 70 %
of the twins who could have survived
five years are now dead .
Dr. Hume: This statement is incorrect.
Dr. Scribner: This was the statement that Don Thomas got from the
group in Boston about two weeks ago.
I do believe that chronic dialysis, based
on our experience, is an accepted
method of treatment. This is borne out
by the world survey that we have just
conducted. In this survey we asked,
"can any well-trained internist, if he
wants to, maintain a patient on chronic
dialysis?", and all 20 investigators
said yes. So, chronic dialysis is no
longer an experimental technique; it is

a therapeutic technique available to
anyone who wants to get in, roll up
his sleeves, and go to work. The problem is that we need time to activate
the units, we need money, and proper
facilities. And, incidentally, with all
due respect to the excellent program
here (at the Medical College of Virginia), they do not have proper faci lities for chronic dialysis on an outpatient basis. The chronic dialysis
program here is solely for the support
of the excellent transplant research
program that is going on.
Dr. Doolan (to Dr. Hurne) : You
mentioned something about someone
overpowering someone. I would find it
hard for anybody to overpower you,
Dave. There really wasn't any argument the way you wound it up, in
that nobody argues with the ultimate
desirability of having an intact kidney
in you. But, let me ask you, how many
transplants with non-maternal donors
have survived over a year?
Dr. Hume: Of the patients that
started off with a non-maternal kidney
that could have survived more than a
year, there were two, and they are
both alive. Of the patients that have
received cadaver kidneys, an unrelated
group, 70 % are still alive.
Dr. Doolan: After one year?
Dr. Hume: No, because they haven't
all been a year.
Dr. Doolan: Dave, will you make
the statement here and now that you,
a surgeon, can guarantee a more than
one-year survival of 50 or 70 % in unrelated homotransplants?
Dr. Hume: Of course not, that
would be a ridiculous statement to
make.
Dr. Doolan: Well, boy, you threw
around an awful lot of statistics. I don't
know whether you are talking about
two weeks, two months, or what.
Dr. Hume: Well , I think the most
important figures in this regard are
that if you take the patients who have
been done more than a year ago, who
are still living at the present time, so
that all of these patients are from one
to two years, and are patients who
couldn't have lived more than a year,
46 % of them are living.
Dr. Doolan: Would you give me that
once more? I'm a. little slow.
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Dr. Hume: Yes. Take the patients
done in the first year of our program.
Our program began August, 1962. All
those patients are now from one to two
years from their transplant. Now take
all the patients who could have lived
during that time-there were 13 such
cases who were done during that year
-six of those patients are now living,
which is 46% of the group. If you
take those patients who have now been
one year, which is not quite the first
year, all told, 44% of patients who
could have lived during that year are
now living.
Dr. Doolan: I would only say that,
as far as I know, unrelated transplants
is strictly an investigative technique
and if you select your patients well,
from what I know of the Seattle group,
it's a therapeutic technique. So, the
only position I'm left with here is
wondering why you have the sensitivity you do in the first place.
Dr. Hume: I have no particular sensitivity. I think that the figures do represent the facts as they are now. I think
it's important to feel that transplantation results are good enough to justify
any investigation on this program. And
I think it's good that the results of
hemodialysis are not so good that one
should settle for this type of therapeutic regimen at the present time.
That's all.
Dr. Scribner: I don't wish to give up
keeping score here, but could I take
advantage of this situation to ask you
to comment on what the fundamental
improvements have been in the technique of transplantation in the past
year or two. I have a feeling that
things are improving.
Dr. Hume: I think the thing we've
perhaps observed better than before
are, first of all, that at the first indication of rejection, immunosuppressive
therapy is increased. Secondly, I think
the use of local radiation has helped
and I think this may be one of the
reasons that our cadaver transplants
are coming along better than some.
This is something that has come out of
the laboratory that seems to help clinically. Thirdly, the use of prednisone
has been extremely valuable in preventing rejection. Fourthly, the preparation of patients for surgery by the
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types of chronic dialysis now available
is .vastly better. We started off with
peritoneal dialysis and now we use the
Scribner technique. Fifthly, I think that
keeping the patients on hand longer
has given us the time to observe them
and manage them better after transplant.
Dr. Doolan: May I make one more
comment in a different vein, Dave, and
that touches on statistics. I recommended for the military section of the
AMA that the treatment of post-traumatic renal insufficiency should be
prophylactic hemodialysis a la Seattle
group technique, which I think is the
finest available. The way I justify this
statistically is that Scribner and Bob
Hagstrom are the only ones that have
lowered mortality rate in acute renal
insufficiency in the post-traumatic
group. To the best of my knowledge,
that's where the issue stands statistically at the moment.
Dr. Scribner: I'm terribly biased in
this regard, but I feel that the prophylactic approach to acute renal failure
just makes eminent good sense as Paul
just very well stated, and since dialysis
in a properly-run center such as you
have here in Richmond is virtually
without risk, and uremia is dangerous
to a person with fractures and so on,
it just is the only way to do it.
Dr. Hume: Thank you very much
for your kind attendance.

"The basic texture of research
consists of dreams into which the
threads of reasoning, measurement,
and calculation are woven".
Albert Szent-Gyorgyi, Introduction to a Submolecular Biology.
New York and London: Academic
Press, 1960, p 1.

Ethics in New Medicine: Tissue Transplants*
FRANCIS D. MOORE
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Conservatism in medicine is a posture of comfort. The physician who
lets a patient go his way with little
more than a squeeze of the hand,
a pain pill, or a knowing look to the
relatives, can console himself that it
has been this way before. It is also
the easiest way. Then when another
physician comes along to state that a
certain disease can indeed be removed,
but by a new and difficult procedure
after careful study by new biochemical
discriminants, the conservative is disturbed. He sees his authority challenged. He feels a deep uneasiness
that many of his ways may soon become outmoded, particularly if he is
inexperienced in, or unable to understand or perform, the new procedure.
He becomes outraged when he discovers that several of the new operations have resulted in fatality rather
than cure. Therefore, with the strong
conviction that he is protecting the
welfare of his patient, he claims that
this new departure is still only experimental, and therefore unethical.
Postgraduate education in medicine
is devoted to surmounting this innate
conservatism. It is a tribute to the
medical profession that each year
thousands of doctors return to sources
of learning to refresh their sense of the
"tried," if not always the "true" in
the sense of widely proven. Practitioners who return periodically to hospitals, where challenge of the old is a
way of life, find that they overcome
this human tendency to entrench, crystallize and defend an unchanging art.
*This paper originally appeared in The
Nation (200: 358-362 'April 5', 1965). It
is reprinted here with the kind permission
of the publisher.

Nevertheless, the history of such
positions against advance, positions
taken on the ground of ethics, is long
and illustrious. It ranges all the way
from the use of ether in childbirth to
the use of aseptic techniques in the
operating room, from the prevention
of puerperal sepsis by isolation to
the removal of brain tumors, and finally includes even the repair of valvular diseases of the heart! An older and
more conservative generation has each
time looked askance at these new
ideas and new procedures and, at
some point in heated controversy, has
declared them unethical.
And yet, some are! Some "innovations" are indeed quite unethical
and unacceptable! How should we
consider the transplantation of goat
glands to restore the waning virility
of the elderly male? Or the treatment
of arthritis by irradiation from outer
space? Or the administration of small
doses of creatinine diluted in water,
to raise the hopes of cancer patients
.. . at a price?
How can the lay person, the legislator or the newspaper writer steer
his way through such controversy?
What values provide guideposts, what
criteria are standards for acceptability
in medical innovation? How is one to
regard the newest entry in this field, an
entirely new kind of surgery: the transplantation of organs from one person
to another?
As new fields of clinical science
emerge, they come under fire from
many directions. The commonest criticism is that new procedures are experimental and therefore their employment in the care of patients is
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immoral. It accomplishes little to point
out that all of medicine is in a sense
experimental, and that most of the
daily tasks in practice-large or small
-are in a very real sense tentative,
insecure. No one can ever take for
granted his mastery over nature. One
must always approach his conquest of
natural forces with a high sense of risk,
of uncertainty and of experiment. One
must seek the same clever skill employed by the glider pilot who rides
air currents that at one moment support him upward , and the next-if
miscalculated-dash him against the
hillside. This simple idea, that applied
human biology involves the hazard of
repeated experiment, applies to all of
medicine and surgery. A few examples
will suffice.
A surgical operation employs bacteriology in just this way. An open
incision bares large areas of sterile
human tissue to the invasive bacteria
of the surrounding world. Cutting,
sewing, dissecting the tissue, an operation becomes an experiment employing techniques of bacteriology to avoid
bacterial infection. If performed properly, the tissues will heal without infection ; if faults and breaks occur,
there is infection. Soon after Pasteur
and Lister showed the bacterial nature
of infection, it became obvious that
"every surgical operation is an experiment in bacteriology."
When a physician gives his patient
digitalis for the first time, he is carrying out an experiment in pharmacology. If he has misjudged the dose because of some unforeseen abnormality
in his patient, he must readjust his
prescription on the basis of the electrocardiogram and the heartbeat, working just as carefully as the scientist
who manipulates a highly controlled
system of variables in the laboratory.
Even such a commonplace operation
as exploratory laparotomy for acute
appendicitis, undertaken as an emergency in the midnight hours, harbors
an element of experiment. "We are
not sure what's the matter with Johnny,
but we better have a look. If it is acute
appendicitis, we can remove the appendix; if it is not, we are running
little risk."
Each patient and each patient's
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disease is different from the last or
the next. Each necessitates a rigorous
approach to the phenomena of nature,
of humanity and of illness. These in
themselves are reasons enough for the
continuing emphasis on biological science in medical education.
When we turn from these everyday uncertainties of medicine and
surgery to the more troublesome aspects of entirely new treatments for
critical illness, we pass from smooth
sailing into choppy waters. The same
experimental aspects are there, but
now uncertainty is accentuated. The
doctor can no longer tell his patient the
chances of success or failure because
he does not know them himself-nor
can he minimize the risk.
At the present time, the patient
dying of kidney failure has but two
things to look forward to, other than
a lingering and unpleasant death. One
is a program of repeated dialyses or
"blood washings" (on the artificial
kidney) at high cost, bringing no possibility of release from the shackles of repeated procedures, sensations of waste
accumulation, and reattachment to the
machine. The artificial kidney has
brought new hope to many patients
with short-term kidney disease capable
of healing and recovery. But for highly
destructive kidney diseases, such as
chronic glomerulonephritis, chronic
pyelonephritis and chronic polycystic
disease, these repeated dialyses are but
a series of temporary makeshifts-a
way of staying alive but hardly a way
of life.
The other choice is to have a kidney
transplantation. This carries many uncertainties and several risks, both at
the operation and later on, as well as
hazards for the donor if a living donor
is used. But despite these factors, kidney transplantation has reached the
point where many patients are now
alive and well, up and about, and at
home and at work, free of repeated
dialyses, but still on medication, with
their transplants working well. To arrive at its present station, however
insecure, this work has taken fifty
years of gradual evolution and fifteen
years of intensive research in America
and Europe.
The first long-term survival after

homotransplant of a kidney (a homotransplant is a transplant between
nontwin members of the same species)
was in the spring of 1962, eight years
after the first identical-twin transplantation. Up to the autumn of 1964, almost 500 kidney transplantations had
been carried out in this country and
abroad, involving many different relationships between donor and recipient. Of these, the large majority have
been done since March, 1963; for
these, no one can possibly claim "longterm survivors!" It is now, as this
procedure is gradually emerging from
a small and tightly controlled research
study to more widespread use, that the
ethical question is being raised: is it
ethical to offer a kidney transplant to
a patient dying of kidney failure?
"Good science is ethical science."
Applied human biology finds meaning
only in assistance for human suffering.
In viewing any new therapy as an
experiment in human biology, it is
possible to draw up certain guidelines
that will support its ethical and moral
climate. These guidelines are much the
same for any medical advance or clinical research, but for each there are
special problems and details to be
served to meet the humane standards
that all must seek.
The first guideline requires that the
patient and his family be brought to
an understanding of the alternatives
through conversation and education. It
is asking too much of a suffering patient to expect from him a final decision; he has neither the dispassionate
view nor the background in biology
required for such a decision. Yet he
must be enabled to understand what
lies ahead, what the possibilities are,
and to enter the procedure of his own
free will and clear assent. Even more
important, this gives him a positive
motivation to aid and assist his doctors.
It is never possible to impose good
surgical care on the unwilling; there is
tangible gain in the confidence and
cooperation that comes from education
and understanding.
This education will tell the patient
and his family what a transplant really
is, how it is done, how it is sutured in
place, the meaning of urine output,
the use of immuno-suppressive drugs
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and many other details. He should
understand the risks, the question of
timing, the utility of repeated dialyses,
the various donor possibilities and the
experience of the hospital group. Any
patient with a good background in
high school biology soon comes to
understand a remarkable amount about
any new medical procedure.
The newest operation needs the
most ancient clinical judgment for
its success; the second guideline is,
therefore, that each patient must receive the best and most experienced
medical care available. No operation
or medical procedure can stand alone.
It succeeds only with the assistance of
all the rest of modern medicine and
surgery, the help of many doctors,
nurses, blood bankers, laboratory technicians, and the participation of that
whole constellation of human activities
encompassed in the modern hospital.
While an isolated research institute
may contribute much to the idea, its
most effective implementation is in
the skilled environment of a busy hospital service. Consultation among doctors provides the checks and balances
that avoid excess of one view, or a onesided bias in interpretation. When four
or five keenly interested persons are
concerned with the patient's care, under the guidance of one of their number, there is a healthy openness of
view that exemplifies the freedom of
communication and sharing of knowledge so essential to the care of complex
illness.
Work on man must be the culmination of an effort, not its initiation; the
third guideline is that preliminary
study in the laboratory by the doctors
doing the work (not someone else!)
must yield enough skill in performance
and likelihood of success to justify
the attempt. The so-called "great advances" of modern medicine, no matter what their nature, have had a sound
basis in laboratory work before they
were moved to the clinic. This basic
laboratory groundwork makes their
clinical application not a mere adventure, but the establishment of a new
routine. When this important guideline
has been neglected, with an attempt to
make the "great leap" straight from
the test tube to the patient, tragedy

has resulted. The one example in the
transplant field wherein the boundaries
of ethical acceptance appear to have
been crossed shows up at this point.
The initial transplantation from chimpanzee to man was well based in
laboratory work on blood grouping;
but the subsequent series of attempts
to place baboon kidneys (and even
other organs, some of them obviously
too small to do the job) in man, represented a premature step based on
inadequate laboratory work. It is quite
possible to set up experimental interprimate heterografts (such as monkey
to baboon, or monkey to anthropoid
apes) which could have tested this
fundamental hypothesis that immunogenetic acceptance might somehow be
achieved more readily than with homografts.
The exact locus of the laboratory in
any advance of applied human biology
depends on the nature of the work to
be done. No dogma is effective for all.
In cancer chemotherapy, for example,
the only available animal model is the
small laboratory rodent-rat or mouse.
Spontaneous or transplantable tumors
in larger vertebrates (permitting study
and care resembling that in man) are
but rarely available. In other fields,
such as active immunization against
poliomyelitis or measles, the final step
somehow has to be made, and it is still
a big one. It involves considerable hazard even though the circumstances are
less spectacular than a surgical operation. The initial test with vaccines is
made cautiously and with small doses.
It should never be done on captive or
primitive populations who cannot understand the risk.
In transplantation research this long
step from test tube to man was taken
only after a decade with the dog. The
size of the dog, the size of his blood
vessels, the ease of his care, the frequency with which blood and urine
tests can be made, and the ability to
judge fine gradations in his clinical
status by physical appearance alone,
have all made study in the dog basic
not only to the science but also to the
ethics of transplantation in man. Antivivisectionists please take note: there
could be nothing more shocking than

moving straight from the rat to man
with the transplantation of organs!
And finally, as a fourth guideline of
the utmost importance, each patient's
case must be studied, documented as
carefully as possible, and made available to the general view. The study and
documentation of each case must be
so complete and accurate that any
interested person can come to the
hospital and spend a few days or weeks
reviewing and challenging the procedure or the data-and learning from
them. There can be no toleration of
secrecy. Every compound used, every
procedure employed, must be fully
known and made clear. When the
time comes, the collected experience
must be published with everything displayed, results both good and bad, so
that the openness of modern science
can be satisfied. There have been no
breaches of this faith in the transplant
field. Several transplant centers have
now banded together to place data on
computers for complete analysis. Any
doctor in the world may join this
project, so that his statistics, his
failures and his successes are freely
made available for all to see.
But helpful as these guidelines are,
no one of them fully answers the
question unique to transplantationwhat about the donor? For the first
time in the history of medicine a perfectly normal, healthy person has now
been subjected to the rigors of a major
surgical procedure and the removal of
an organ, to help another.
The principle of injury to one so as
to help another is common throughout
nature and is basic to the Christian
ethic. Examples are not to be found in
the protection of its young by hazard
to the mother, or when one person has
sacrificed himself to help another, in
war or peace. But in these natural
phenomena and altruistic events, there
has never been a third party-the
physician-advising the individual to
take this risk. It has been an emotional
rather than an intellectual decision,
and a matter of personal choice.
Medical science began to invade
this field about 1915, with the development of blood donation for transfusion. Here the injury appeared to be
minor and the body had methods to
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compensate. TJIJ.e hazard in blood donation lies not in any threat to the
donor but in the threat to the recipient
by the transmission of disease.
The initial step in organ transfer was
taken in 1954, with the first of the
identical-twin transplants. Up to September, 196 ~\, thirty-three identicaltwin transplants have been carried out
in the world, of which twenty-two are
still alive with kidneys functioning
well. The success of identical-twin
transplantation has become sufficiently
assured so that it scarcely arouses a
question of morality with regard to
the recipient-who is dying from terminal kidney disease. But as it bears
on the donor, the ethical problem is as
pressing and urgent now as it ever
was, and is just as severe for the
identical-twin donor as it is for the
unrelated person, or for the father,
mother or brother who seeks to be a
kidney donor.
There is no simple unitary ethical
solution for kidney donation from a
living person today. Nephrectomy (removal of a kidney) carries a risk and a
mortality. When enough have been
done, it will be found that one has resulted in fatality. When enough have
been done, it will likewise be found
that a subsequent injury to the opposite
kidney has resulted in significant loss
of function, shortening life. The likelihood of a donor's losing the use of
his remaining kidney is very small, and
has been estimated as being in the same
range as an automobile fatality, yet
probabilities and statistics are inescapable. Such a major procedure as nephrectomy will surely exact its price
when finally enough have been done.
It is clear that the first priority in
donor development lies in better
methods for preserving kidneys from
recently deceased persons-a situation
that completely side-steps the use of
the living donor. This is still a research
problem (though many cadaver kidneys have functioned well), but it is a
research problem with an ethical overtone. Until cadaver kidneys can be
used for all, the living donor (closely
related to the recipient) still yields the
best chance for success. Some important principles appear to be as follows:
First, every effort should be made
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to assure the maximum donor-recipient
tissue compatibility. Despite advances
in this area during the past year or two,
the most reliable criterion is still that
of close family relationship.
Second, one must be assured that
both kidneys of the donor are quite
normal, that there is no disease of the
upper or lower urinary tract, and that
kidney donation will involve only the
risk of nephrectomy itself.
Third, the donor, just as the recipient, must understand the risks, the
alternatives, the hazards, the discomforts, and most especially the uncertainties in the enterprise. If the donor
is an identical twin, the prospects for
success can be described with reasonable optimism. If any other relationship,
then the prospects in all their uncertainty must be outlined clearly.
But surely the most important thing,
as mentioned above, is to move away
from the living donor entirely. This
requires intensive study of cadaver
organ procurement, and the definition
of those factors in the recently deceased that bias the health of the
remaining tissues. When the brain and
heart are dead, then the patient is
said to be "dead," even though many
of his tissues are still alive, respiring
in a blood stream increasingly devoid
of oxygen, accumulating acid, but still
alive for a few more minutes and salvageable for life in a new host. The
care of the dying patient must never
be compromised by impending tissue
donation. The finest tissue bank in
the world is the body of a person
recently deceased from causes not
damaging the health of transplantable
tissues. Death from certain types of
injuries, heart disease or brain tumors
has provided many useful tissues. If
cancer, infection, chronic vascular disease or just plain old age enter the
picture, then the organs are of little
use or actually dangerous to another.
Herein lies a whole new field of endeavor in which we, as doctors, need
the help of lawyers and legislators to
give us legal guidelines to steer us
through the uncertainties.
It is ironical to find that while tissue
transplantation itself is being called
into ethical question, in point of fact
it is giving an entirely new meaning to

human generosity as living persons or
families of those recently dead make
free donations of tissue for the assistance of others. The ethical lesson of
kidney transplantation may turn out
to be on the side of the Good Samaritan rather than the Evil Scientist!
It is a curious fact that although the
general questions of ethics are not
appropriate for examination by the
methods of science, nonetheless a
strong ethical flavor runs through all
of science-"good science is ethical
science." What are these features
within science which give it ethical
stature?
"Experiment is perilous and decision
difficult." In that well-worn phrase,
"perilous" and "difficult" indicate two
of the ethical values in scientific experiment: courage and persistence. Other
values have to do with rigorous personal honesty in viewing and displaying the results of scientific research,
without prejudice, with a dispassionate
discrimination, and with the selfdiscipline required to make a judgement
valid. Those who enjoy the privilege
of science must spend many years acquiring an education so as to make
their work meaningful. Ethical value:s
in science include also such things as
openness of communication, exchange
of information, avoidance of secrecy,
willingness to educate the young and
the avoidance of selfish gain.
Every few years the public is affronted by some spectacular example
wherein a self-styled scientist has
kicked over these traces, and sought
a quick victory over nature by disobeying these inner ethics of science.
But science is a stern taskmaster; transgressors are brought to a bitter judgment.
Examples are to be found in those
goat-gland transplants. Though hardly
science in any term, they were most
assuredly devoid of the ethical content
of careful study, openness of method,
documentation, and analysis of results.
The Nuremberg trials showed us
another failure of ethics in experimentation. When a so-called "scientific
experiment" was conducted wholly at
the expense of the welfare of human
beings, nothing good came of it. Even
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the experimenter himself was finally
debased and prostituted.
Most recently in the public press
there has been described a flagrant example, where in science has shown that
its own inner ethic must indeed be
obeyed and respected. A person of
previous scientific achievement has
evidently tried to convince the public
of the effectiveness in cancer treatment
of a compound the identity of which
he kept a secret-and indeed it truly
was a secret, because as it now turns
out, he himself did not know what it
was! Instead of education and openness, careful trial, clear publication,
controlled results, documentation of
good and bad clearly shown for all to
see, advocacy here was on the basis of
hearsay about a secret and unknown
compound, based on testimonials from
random patients. A travesty on all the
guidelines we have discussed! And
then, with a fitting irony, downfall
came through the study of a scientist
working in the laboratory and obeying
the basic ethic of honesty and rigorous
examination. While examining this
highly publicized "cancer cure" by
infrared spectroscopy, he found it to
be creatine-a commonplace material
present in large amounts in the bodies
of all cancer patients.
The study of patients is always more
difficult and complicated than the study
of controlled experiments in the laboratory. Sick people can be difficult, demanding, biased and fickle; controls
are hard to conceive and devise. The
patient's own emotional involvement
and that of the doctor himself often
provide false evidences of success.
Persons working in clinical research
(research in patient care) are as much
in need of special education for this
complex work as is the physiologist
working under highly controlled conditions in the quiet of his laboratory.
Five years ago, the field of tissue
transplantation was in a very difficult
phase of clinical research. Then came
the demonstration of immunosuppressive pharmacology by scientists
working with the New Zealand white
rabbit. There was then a period of advance clear for all to see as studies in
the dog confirmed their findings and
were moved to man. But now again the

field of tissue transplantation has been
advancing more slowly, awaiting its
next stepwise upward progression. As
this is written, several new modifications are coming along, any one of
which might make tissue transplantation sa:er and more effective. Until
then, the toilers in this vineyard must
work with the methods they have, respecting some such guidelines as these,
for ethics in the pursuit of veritas.
It is most appropriate to raise
ethical questions at a time like this,
not only to strengthen and shore up
the procedures of each group working
in the field of transplantation but also
to challenge the critic and put him
on his mettle to show cause why this
particular advance of medical science
should be any more suspect than
another. The laboratory scientist tends
to be critical of the clinician, the
physician of the surgeon; these petty
chauvinistic antagonisms should never
cloud the real issues of ethics and
acceptability in applied human biology.
Tissue transplantation, like other advances of the past, will react to the
welfare of mankind if explored and
exploited within the ethical bounds of
science itself. Honesty and self-discipline must be held as values of the
same importance as the very essence
of all medical ethics: the welfare of
the patient.
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The Frequency and Natural History
of Urinary Tract Infection in
School Children*
CALVIN M. KUNIN

Departments of Preventive Medicine and Medicine, University of Virginia
School of Medicine, Charlottesville

This presentation reviews briefly
investigations of the epidemiology and
natural history of urinary tract infections in school children conducted during the past four years in Central Virginia. The results of this work will be
summarized and their implications discussed.
Urine Culture Methods

The clean-voided , quantitative pourplate urine culture was performed
throughout. Cases were defined as
children with three consecutive positive cultures (criterion 1 X 10° bacteria per ml). Almost all cases were
confirmed by culture of urine obtained
by catheter at the time of the urologic
study. E . coli were serotyped according to their 0 and H antigens.
The Population

Following a pilot study of 3,057
children in Waynesboro, Virginia, in
1959, full scale surveys of school children
in
Charlottesville-Albemarle
County, Virginia, were conducted in
1960-61 and 1962-63. Participation
was 85% in the pilot study and 90 %
of all children enrolled in school in the
full scale surveys. Altogether, more
than 20,000 cultures have been performed on specimens from 16,000 per-

* Presented at the Second Annual Kidney Symposium, Virginia Chapter, National Kidney Disease Foundation, Richmond, October 16, 1964.
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sons. A prospective study of a cohort
of girls begun when they first enrolled
in school is still underway.
Frequency of Bacteriuria

The prevalence of bacteriuria was
1.2% in school-aged girls and 0.04 %
in school-aged boys. Prevalence was
about the same in Negro and white
girls, equally distributed in urban and
rural areas and constant in all three
studies. The prevalence of silent bacteriuria was significantly higher in
older Negro girls (15-19) than in white
girls or younger Negro girls. Incidence of silent bacteriuria over a twoyear period was 0.7 % and the same in
whites and Negroes. Incidence of overt
urinary tract infection in school girls
during the same period was 3.6 % and
higher in white than Negroes (5 .3%
and 1.1 % respectively).
Characteristics of Cases

One hundred and twenty two bacteriuric children were discovered in
these surveys. Pyuria (four or more
WBC/ hpf) was present in almost 50 %;
past history of overt infection was reported by almost one third; and 40 %
had symptoms, usually referable to
the lower urinary tract. Urologic studies (IVP and cystogram) were performed in 107 cases. Intravenous pyelograms revealed some abnormality in
22; caliectasis was present in 14; and
4 had reduplication of the collecting
system. Cystograms revealed some ab-

normality in 40 children including reflux in 20, large bladder in 11, small
bladder in 5 and trabeculation in 13.
Lesions detected on IVP and cystogram were significantly (P < .05) more
frequent in white than Negroes. Pyuria, past history of infection and
symptoms were not reliable indicators
of the presence or absence of abnormalities later found on urologic study.
Therapy and Recurrence

Most cases were initially treated
with sulfonamides for a period of two
weeks. Recurrences were first treated
with a second course of sulfonamide
and, if frequent, with tetracycline, nitrofurantoin or other appropriate
drugs. Recurrences were frequent. For
example, at the end of one year, 65%
of white girls had at least one recurrence. The recurrence rate in Negro
girls (18.2 % ) was significantly lower
than in whites (P < .01) at one year.
Recurrences were analysed as being
due to endogenous relapse (recurrence
of the same E. coli serotype or same
bacterial species other than E. coli) or
to reinfection (appearance of a new E .
coli serotype or a new species in the
urine) . Most recurrences (about 80%)
were thought to be due to reinfection
rather than to endogenous relapse, and
possibly related to inadequate therapy.
This indicates that this population with
cases of bacteriuria is distinctly different from the general population of
school children in which bacteriuria is
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relatively rare. One possible implication is that females who develop pyelonephritis during the reproductive years
emerge from this group of children
with frequently recurrent bacteriuria.
Frequency of recurrences could not
be related to the previous findings of
caliectasis, reflux or trabeculation on
urologic study, suggesting that the entrance and persistance of bacteria in
the urine is not related to these abnormalities. This does not necessarily indicate that structural abnormalities
may not be important in the genesis
of infection of the upper urinary tract
once bacteriuria is established.
Antibody Response to Infection

All children studied over the age of
two had circulating antibodies to a
wide variety of E. coli 0 antigens including those most commonly found in
children (reported by us) and adults
(reported by others). The common
types of E. coli are 0, 1, 2, 4, 6, 7, and
75. Enteropathic E. coli were not
found in urinary tract infections. A
rise of antibody titer in association
with bacteriuria was rarely observed
in the current series of cases and persistence of constant antibody titers for
many months was commonly observed.
Summary

This brief summary of our studies
of urinary tract infection in school
children indicates that bacteriuria is
frequent enough among girls to make
surveys of this type quite practical
both as a community effort and an
office practice. The ultimate significance of bacteriuria is unknown, but
about 10% of the cases found had important urologic lesions (including the
megacystis syndrome) which would
not have been detected if these studies had not been conducted. Long term
follow-up of cases, now underway,
may help to determine the true significance of bacteriuria.
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The Scholar as
a Teacher

" ... I hold that no teacher-no
matter how skilled-can so well
present a subject as when he himself is working in that field. It is
a truism that a member of a university community of scholars
must himself be engaged in scholarly work. There is nothing like
the combination of clinical problems at the bedside and dirty hands
in the laboratory to teach the
teacher. A prime prerequisite for
scholarly work is a curious and
inquiring mind. Attempting to answer any single question in depth
soon disciplines omnivorous curiosity. Many problems can be approached only by carefully planned
and slowly developed data, and no
problem is solved until it is formulated and worked out and the
data analyzed and published. 'Publish or perish' is more than a
scoffer's jibe. The investigator who
does not publish his results has
not completed his research problem, made full use of his data, or
justified the financial support intended to increase available human
knowledge. 'Reading maketh a full
man; conference a ready man; and
writing an exact man.' And I mean
writing for professional journalsnot for the lay press. It is also true
that when a problem presents itself on the ward or in the clinic,
nothing is more apt than Claude
Bernard's aphorism, now 99 years
old, that 'chance favors the prepared mind' (Bernard, C. Introduction a l'Etude de la Medicine
Experimentale. Paris: Bailliere,
1865).
"The exact influence of research
on teaching is, of course, hard to
assess. Certainly enthusiasm is an
important teaching instrument, and
the person intensely engaged in
work on a subject about which he
is teaching is the best possible
person to create an enthusiastic
reception on the part of the student. To my mind, a scholar who is
himself working on the subject
which he teaches is also the person
most aware of the pitfalls, dubieties, uncertainties and qualifications involved. Such caution should
contrast greatly with the glib veneer of the nonscholar. Glib over-

simplification may sell soap, but it
should not be the tool of the scholar.
In the academic community, teaching is not a popularity contest and
the teacher must aim at clarification rather than simplification.
Who knows better the limitations
of knowledge than the man who is
himself striving to extend the frontiers of that knowledge?"
Gilbert S. Gordon, M.D.,
Credo, Postgraduate Medicine 36: 630-633, 1964.
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'Y-Globulin Administration and Anti-Globulin
Antibodies in Children*
MARION WALLER AND NELLIE CURRY
\

Department of Medicine, Medical College of Virginia, Richmond

The etiology of the rheumatoid factors in patients with rheumatoid arthritis and of anti-globulin antibodies
in normal individuals remains obscure
despite recently documented observations. Allen and Kunkel (1963) and
Vierucci (1965) have reported an increased incidence of anti-globulin
antibodies in children who received
multiple transfusions for chronic anemia. Fudenberg et al. (1964) and
Stiehm (1965) found that children who
had been receiving repeated y-globulin
injections were more prone to produce
anti-globulin antibodies than children
not exposed to y-globulin. These data
furnish indirect evidence of the isoantigenicity of genetic determinants in
human y-globulin. From the clinical
standpoint, the observations are of interest to pediatricians administering
y-globulin to children whose sera show
low levels of y-globulin, and whose
clinical courses are characterized by
repeated or chronic infections.
This study was undertaken to determine the incidence of anti-globulin
antibodies in non-hospitalized children
with chronic or recurrent upper respiratory infections, only some of
whom had received y-globulin injections.
Materials and Methods

The 185 children studied were under

* Supported by Public Health Service
Research Grants AM 04549 GM and
Tl AM 5056. This is the second publication from the Charles C. Thomas Arthritis Fund.
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the care of their private physicians or
attended the pediatric clinic. Hospital
patients were not included. With the
cooperation of the participating physicians, history forms were completed on
each child, recording age, race, sex,
the amount and duration of globulin
therapy, reason for administering yglobulin, transfusion history, and
whether or not joint symptoms were
present. All children with a transfusion
history were excluded from this study
in order to obtain a more uniform
population.
The 44 children who had received
y-globulin injections had y-globulin
levels less than 500 mg per 100 ml.
The duration of y-globulin therapy reflected to some degree the course and
duration of their respiratory infections.
The 141 children who had "never" rereceived any y-globulin comprised the
largest group. Although these children
were recorded as "never" having had
y-globulin, it has been customary for
some physicians to give a small amount
of y-globulin with measles vaccine.
Some of these 141 children were tested
before the initiation of y-globulin
therapy. Thus, these children do not
necessarily represent a group of children with normal levels of y-globulin.
All sera were tested at a 1 : 20 dilution by: the slide latex test (Hyland),
the sensitized human cell test, and the
sensitized sheep cell test. These tests
have been described previously (Waller
et al., 1961). In addition, most of the
sera were tested at a 1 : 5 dilution with
selected sensitized cells known to detect anti-Gm•, Gm", Gmx and Gm'
activity.
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Results
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Anti-globulin Antibodies
Of the 185 children studied, only 44
had received injections of y-globulin
at the time of testing. All of these children were tested at a 1 : 20 dilution of
their serum with the slide latex test
and the sensitized human cell test. The
latex test was strongly reactive in only
one child and weakly reactive in 12
children . Only one of these 13 children
had received y-globulin injections. The
human cell test was positive in eight
children (4.3 % ), only one of whom had
received y-globulin. This incidence does
not differ significantly from that characteristic of the normal adult population (Waller et al., 1964). The sensitized sheep cell test (Waaler-Rose
Test) was performed on 135 children,
including all children found to be positive by any of the other tests. In no
instance was a positive sheep cell test
observed.
Since the titers of anti-globulin antibodies in normal individuals may often
fall below 1: 20, 140 of the original
185 children were tested at 1 : 5 dilution of their serum with Ripley sensitized cells. Eighteen children ( 12.9 % )
gave positive tests at this dilution. However, of these 18 children with positive
tests, only three h ad received injections
of y-globulin.
Thus, to look at the results in another way, of the 108 children who had
not received injections of y-globulin
and whose sera were tested at a 1 : 5
dilution, 15 (13 .9 % ) gave positive
tests. However, of the 32 children who
had received y-globulin and whose
sera were tested at a 1 : 5 dilution, only
three (9.4 %) gave positive tests. These
differences are probably not statistically significant (p > .4).
Figure 1 compares the titers of antiglobulin antibodies in children who
had received y-globulin injections with
those who had not received any yglobulin. The left bars, 1 : 5, represent
the negative group in our study, since
the children were not tested at a level
below 1 : 5. Ten children gave titers of
1 : 5, but only two of these had had
y-globulin. Eight children had titers
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Fig. 1-Titers of anti-globulin antibodies in 32 children who had received "(-globulin
injections, and 108 who had not.

above 1 : 5, but only one child had had
y-globulin. Thus, among the 44 children who had received injections of
y-globulin, only three children gave
positive tests for anti-globulin antibodies. There was no correlation between the amount of y-globulin administered, the duration of globulin
therapy, and the presence of a positive test for anti-globulin antibodies.
Three children had had in excess of
100 ml of y-globulin over a period
from one to three years, and all gave
negative tests at 1 : 20 dilution of their
serum . Two of the three were also
negative at 1 : 5 dilution of their serum.

Gm Specificity
Antibodies

of

Anti-globulin

In addition to the sensitized human
cell test (Ripley), four other anti-D
sera were used to sensitize cells for Gm
specificity of the children's sera. Ninety
children were tested for Gm specificity.
Of these 90 children, 10 agglutinated
the Ripley sensitized cells and five of
the 10 agglutinated one or more of
the other sensitized cells. Of these 10
children, five gave specific anti-Gm
activity, one anti-Gm(f), one antiGm(x) , and three anti-Gm(a). The
sera of the other five children agglu27
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tinated only the Ripley sensitized cells,
and it was not possible to obtain Gm
specificity. Of the five children whose
sera showed specific anti-Gm activity,
only one had received y-globulin.

Lack of Correlation between Presence of Anti-globulin Antibodies and
Level of y-globulin or Age of Children
There was no apparent correlation
between the presence of hypogammaglobulinemia ( < 500 mg per 100 ml)
and the presence of anti-globulin antibody. There was also no correlation
between the ages of the children and
the presence of anti-globulin antibody.
Among the children up to three years
of age, 12% gave positive tests for
anti-globulin antibody at a 1 : 5 dilution of their sera. Among the children
over three years of age, 13.7% gave
positive tests. Of the 185 children
studied, four children gave history of
joint complaints, none had had y-globulin at the time of the study, and none
had anti-globulin antibodies demonstrable in their sera.

Injection of y-Globulin into Adults
We have studied the effects of subcutaneous injections of pooled y-globulin in four young healthy male volunteers. These men were all Gm(a-)
and received (.5 ml) injections of pooled
y-globulin weekly. In addition to tests
for anti-globulin antibodies, slide latex
tests, and sensitized sheep cell tests, the
following tests were performed: serum
electrophoretic pattern, sedimentation
rate, hemoglobin, and total protein.
Two of the volunteers received a
total of eight injections of y-globulin
over a period of three months and two
received 16 injections over a period of
one year. In no instance did these four
individuals produce anti-globulin antibodies, nor were any changes noted in
the other tests performed.
Discussion

Although the incidence of anti-globulin antibodies in children receiving
multiple transfusions is markedly increased, we were not able to demonstrate this increased incidence in the
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children receiving pooled y-globulin.
There are several possible explanations
for these observed differences. The
children receiving multiple transfusions
had a definite disease entity while the
children that we studied were "normal"
except for chronic or recurrent upper
respiratory infections. The evaluation
of just how chronic, recurrent, or severe the infection rested with the individual physician; however, all of the
children studied had electrophoretic
patterns of their serum performed as
a consequence of the degree or duration of their infection. No attempt was
made in this study to separate the
children according to degree or duration of their illnesses. Certainly, the
children were not ill enough to require
hospitalization during the period of
this study.
It is possible that plasma is more
antigenic than pooled y-globulin or
that the globulin administered intravenously is a better antigen than when
it is administered intramuscularly. In
addition, the children receiving multiple transfusions received more plasma
for a longer period of time than did
the children receiving pooled y-globulin.
Stiehm and Fudenberg (1965) studied 14 hypogammaglobulinemic children who had received many y-globulin injections and found that nine of
these children (64.3%) had developed
anti-globulin antibodies. Among the
24 untreated siblings of these children,
only two agglutinators were found
(8.3% ). We are not able to explain the
discrepancies in these results other
than by the fact that we did not use as
controls the siblings of the hypogammaglobulinemic children. However, in
addition, one may presume that the
untreated siblings were untreated because they were not hypogammaglobulinemic or that they were not
subject to chronic or recurrent infection. Some of our untreated children
were hypogammaglobulinemic and
most were subject to chronic infection.
After the testing of their sera, some
children were started on y-globulin
therapy.
Since an equal number of our children who had not received y-globulin
produced anti-globulin antibodies, pre-
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sumably other, as yet unknown, agents
are as likely to stimulate the production of these antibodies as is the administration of pooled y-globulin.
Steinberg and Wilson (1963) studied
eight non-transfused donors of yglobulin antibodies and found that in
each instance the donor's mother had
the globulin factor that the donor
lacked. They assumed that the donor's
antibody was formed as a result of
transplacental isoimmunization. However, we have been unsuccessful in our
attempts to elicit anti-globulin antibodies in normal adult Gm( a-) volunteers by the injection of pooled yglobulin.
There is no definitive evidence that
the serological reactions called rheumatoid factors in patients with rheumatoid arthritis and anti-globulin antibodies in normal individuals, differ
except in strength of reaction (titer)
and possibly in specificity. Not all investigators are convinced that the idea
of an antigen-antibody relationship for
y-globulin (Gm) and anti-globulin reagents (anti-Gm) in man is firmly established (Grubb, 1961). Certainly,
the deleterious effects of the serological reactions called "rheumatoid factors" have not been proven at the
present time. Regardless of these unresolved questions, it is not established
that the isoantigenicity of y-globulin
is such as to override its therapeutic
potential in infection.
Summary

for sending us some of his young patients who had been on long-term
y-globulin therapy. We also thank Miss
Jane Atkinson for providing us with
most of the sera used in this study.
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Panelists at the Second Annual Kidney Symposium; from left, Drs. Kiley, Doolan,
Scribner, Finberg, Magee, and Hume.
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